LSTA Key Statistics, Chart & Performance
The current stock price of LSTA is 1.96 USD. In the past month the price increased by 1.82%. In the past year, price decreased by -49.09%.
LSTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About LSTA
Company Profile
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Company Info
LISATA THERAPEUTICS INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY US
Employees: 26
Phone: 19082292590
LISATA THERAPEUTICS INC / LSTA FAQ
What does LISATA THERAPEUTICS INC do?
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
What is the current price of LSTA stock?
The current stock price of LSTA is 1.96 USD. The price increased by 5.38% in the last trading session.
Does LISATA THERAPEUTICS INC pay dividends?
LSTA does not pay a dividend.
What is the ChartMill technical and fundamental rating of LSTA stock?
LSTA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is LSTA stock listed?
LSTA stock is listed on the Nasdaq exchange.
Can you provide the market cap for LISATA THERAPEUTICS INC?
LISATA THERAPEUTICS INC (LSTA) has a market capitalization of 17.29M USD. This makes LSTA a Nano Cap stock.
What is the outstanding short interest for LISATA THERAPEUTICS INC?
The outstanding short interest for LISATA THERAPEUTICS INC (LSTA) is 0.22% of its float.
LSTA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LSTA. When comparing the yearly performance of all stocks, LSTA is a bad performer in the overall market: 90.2% of all stocks are doing better.
LSTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LSTA. The financial health of LSTA is average, but there are quite some concerns on its profitability.
LSTA Financial Highlights
Over the last trailing twelve months LSTA reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 15.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.84% | ||
| ROE | -105% | ||
| Debt/Equity | 0 |
LSTA Forecast & Estimates
9 analysts have analysed LSTA and the average price target is 13.26 USD. This implies a price increase of 576.53% is expected in the next year compared to the current price of 1.96.